Monitoring drug levels in patients with Staphylococcus aureus infections
Plasma Pharmacological Monitoring of M Penicillins in Methicillin-sensitive Staphylococcus Aureus Bacteremia - Single-center Retrospective Study
University Hospital, Strasbourg, France · NCT06495697
This study looks at how well doctors can monitor drug levels in adults with Staphylococcus aureus infections to make sure they get the right amount of medication and stay safe during treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Strasbourg, France (other) |
| Locations | 1 site (Strasbourg) |
| Trial ID | NCT06495697 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients with Methicillin-sensitive Staphylococcus aureus bacteremia treated at the University Hospitals of Strasbourg. It aims to monitor plasma levels of M penicillins, such as oxacillin and cloxacillin, to prevent overdosing, which can lead to nephrotoxicity and neurotoxicity. The study will analyze data from adult patients treated between January 1, 2019, and December 31, 2022, to assess the relationship between plasma levels and clinical outcomes. The goal is to optimize dosing and improve patient safety during treatment.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who have been diagnosed with Staphylococcus aureus infections and treated at the University Hospitals of Strasbourg.
Not a fit: Patients who have opted out of data reuse for scientific research will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to safer and more effective treatment protocols for patients with Staphylococcus aureus infections.
How similar studies have performed: While the specific approach of monitoring plasma levels in this context may be novel, similar studies have shown that careful dosing can significantly improve patient outcomes in antibiotic treatment.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patient (≥18 years old) * Having presented an infection with Staphylococcus aureus and treated at the University Hospitals of Strasbourg between January 1, 2019 and December 31, 2022. Exclusion Criteria: - Patient having expressed his opposition to the reuse of his data for scientific research purposes.
Where this trial is running
Strasbourg
- Service des Maladies Infectieuses et Tropicales - CHU de Strasbourg - France — Strasbourg, France (RECRUITING)
Study contacts
- Study coordinator: Baptiste HOELLINGER, MD
- Email: baptiste.hoellinger@chru-strasbourg.fr
- Phone: 33 3 69 55 05 45
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Staphylococcus Aureus Infection, Staphylococcus aureus Infection, Staphylococcus aureus bacteremia, Penicillins, Methicillin-sensitive, Cefazolin, Infectious endocarditis, Staphylococcal endocarditis